Skouby S O, Mølsted-Pedersen L, Kühl C, Bennet P
Fertil Steril. 1986 Nov;46(5):858-64. doi: 10.1016/s0015-0282(16)49825-0.
The metabolic effects of four oral contraceptives with different estrogen/progestogen profiles (monophasic nonalkylated estrogen/norethindrone, low-dose monophasic ethinyl estradiol (EE2)/norethindrone, progestogen only treatment with norethindrone, and triphasic EE2/levonorgestrel) were examined in insulin-dependent diabetic women. During the 6-month study period, no differences were found in fasting plasma glucose, 24-hour insulin requirements, glycated hemoglobin, free fatty acids, low-density lipoprotein cholesterol concentrations, or high-density lipoprotein cholesterol/total cholesterol ratio between the patients in each treatment group. Compared with the nonalkylated estrogen/norethindrone and the triphasic EE2/levonorgestrel formulations, the low-dose EE2/norethindrone combination resulted in small but significant increases in plasma triglyceride and very low-density lipoprotein cholesterol levels (P less than 0.01), which seemed unfavorable from a clinical point of view. Norethindrone-only treatment appeared to be an appropriate alternative to both the nonalkylated estrogen/norethindrone combination and the triphasic EE2/levonorgestrel formulations.
在胰岛素依赖型糖尿病女性中研究了四种具有不同雌激素/孕激素特征的口服避孕药（单相非烷基化雌激素/炔诺酮、低剂量单相乙炔雌二醇（EE2）/炔诺酮、仅用炔诺酮进行孕激素治疗以及三相EE2/左炔诺孕酮）的代谢效应。在6个月的研究期间，各治疗组患者之间在空腹血糖、24小时胰岛素需求量、糖化血红蛋白、游离脂肪酸、低密度脂蛋白胆固醇浓度或高密度脂蛋白胆固醇/总胆固醇比值方面均未发现差异。与非烷基化雌激素/炔诺酮和三相EE2/左炔诺孕酮制剂相比，低剂量EE2/炔诺酮组合导致血浆甘油三酯和极低密度脂蛋白胆固醇水平小幅但显著升高（P小于0.01），从临床角度来看这似乎不利。仅用炔诺酮治疗似乎是替代非烷基化雌激素/炔诺酮组合和三相EE2/左炔诺孕酮制剂的合适选择。
